Changes in Circulating Cytokines and Adipokines After RYGB in Patients with and without Type 2 Diabetes.
Where this comes from
- Record sourced from PubMed, PMID 33624436.
- Also identified by DOI 10.1002/oby.23093 and PMC identifier 7986425.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This study aimed to compare cytokine and adipokine levels in patients with obesity with and without type 2 diabetes (T2D) at baseline and 6 months after Roux-en-Y gastric bypass (RYGB) with healthy controls. A total of 34 patients (21 with T2D) with BMI of 30 to 45 kg/m<sup>2</sup> were compared with 25 healthy controls without obesity. Cytokines, adipokines, and peptides of relevance for inflammation and metabolism were analyzed in plasma. Significant decreases in weight and glycated hemoglobin A<sub>1c</sub> were observed. At baseline, interleukin-6 (IL-6), IFN-β, IL-18, leptin, and hepatocyte growth factor were higher in all patients with obesity compared with healthy controls. In patients without T2D, TNF-α, IL-1α, IL-2, IL-15, and visfatin were also increased, whereas bone morphogenic protein-4 was decreased. Following RYGB, IL-6 and hepatocyte growth factor were still increased in both groups compared with controls. In T2D patients, IFN-β, IL-27, IL-1α, IL-2, regenerating islet-derived protein 3A, visfatin, and osteopontin were found to be increased. In patients without T2D, TNF-α, IL-1α, IL-2, IL-15, leptin, and visfatin remained increased. The altered cytokine profile of patients with obesity persisted after RYGB despite large weight loss and improved metabolic status, thus reflecting an inherent inflammatory state.
Medical subject headings
- Adipokines
- Cytokines
- Diabetes Mellitus, Type 2
- Gastric Bypass
- Obesity